⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 28, 2024BMC CancerOpen Access

Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response

Shengshan Xu Youbin Zheng Min Ye Tao Shen Dongxi Zhang Zumei Li Zhuming Lu

View Full Paper

Ask AI

Bookmark

Share

Abstract

Recent studies have increasingly linked Ephrin receptor B2 (EPHB2) to cancer progression. However, comprehensive investigations into the immunological roles and prognostic significance of EPHB2 across various cancers remain lacking.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xu et al. (2024) studied this question.

synapsesocial.com/papers/68e5a818b6db64358754254b https://doi.org/10.1186/s12885-024-12843-0

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comprehensive analysis of <scp>EphA2</scp> in pan‐cancer: A prognostic biomarker associated with cancer immunity2024 · 9 citations
2High levels of EPHB2 expression predict a poor prognosis and promote tumor progression in endometrial cancer2025
3A pan-cancer analysis of EphA family gene expression and its association with prognosis, tumor microenvironment, and therapeutic targets2024 · 1 citations
4Silencing EPHB2 diminished the malignant biological properties of esophagus cancer cells by blocking autophagy and Wnt/β‐catenin pathway2024 · 1 citations
5Prognostic and therapeutic value of the Eph/Ephrin signaling pathway in pancreatic cancer explored based on bioinformatics2024 · 4 citations